3-Cl-PCP

coronary artery disease, hypertension, heart failure, conduction abnormalities, long QT syndrome

PCP-class compounds produce dose-dependent tachycardia and hypertension via monoamine reuptake inhibition. In silico modeling for PCP analogs predicts hERG channel inhibition (IC50 ~4.9–12.3 µM), suggesting risk of QT interval prolongation and cardiac arrhythmia. Pre-existing cardiovascular disease compounds these risks. No substance-specific cardiovascular data exist for 3-Cl-PCP.

concurrent amphetamine use, concurrent cocaine use, concurrent MDMA use

PCP-class compounds inherently inhibit monoamine reuptake. Adding exogenous stimulants compounds dopaminergic activation, increasing risk of hypertensive crisis, hyperthermia, and acute psychosis. The convergence of NMDA-mediated dissociation with stimulant-driven dopamine surge may produce unpredictable psychiatric destabilization.

concurrent opioid use, concurrent benzodiazepine use, concurrent alcohol use, concurrent GHB use

Combining dissociatives with CNS depressants (opioids, benzodiazepines, alcohol, GHB) produces synergistic respiratory depression and loss of consciousness. A systematic review of dissociative overdose deaths found polydrug use in 53% of ketamine-related fatalities (Chaves et al. 2023). This is the highest-risk interaction category for the arylcyclohexylamine class.

concurrent lithium therapy

Lithium combined with NMDA antagonist dissociatives increases seizure risk. This interaction has been documented for ketamine and methoxetamine (Zanda et al. 2016). The seizure-threshold-lowering properties of PCP-class compounds compound lithium's pro-convulsant potential at toxic levels.

schizophrenia, schizoaffective disorder, personal or family history of psychosis

PCP-class NMDA antagonists are among the most potent pharmacological psychotomimetics. They reproduce the full triad of schizophrenia-like symptoms — positive (hallucinations, delusions), negative (social withdrawal, flattened affect), and cognitive (working memory impairment, disorganized thought). 3-Cl-PCP produced dose-dependent psychosis-like cognitive deficits in the only published behavioral study (Shaw et al. 2024). Use in individuals with pre-existing psychotic disorders or a family history of psychosis carries extreme risk of prolonged psychiatric decompensation; case reports for the closely related 3-MeO-PCP document hallucinations persisting up to six weeks.

cirrhosis, hepatic insufficiency, acute liver disease

PCP undergoes approximately 90% hepatic clearance via CYP2B6, CYP2C19, and CYP3A4. Significant hepatic dysfunction could produce dangerous drug accumulation and prolonged pharmacological activity. Additionally, in silico modeling predicts liver as a target organ for PCP analog toxicity (probability up to 0.91), suggesting hepatotoxic potential that would be compounded by pre-existing liver disease.

chronic kidney disease, acute kidney injury history

While renal excretion of unchanged drug is minor (~9%), PCP-class compounds carry significant rhabdomyolysis risk via sustained involuntary muscle contraction, agitation, and hyperthermia. Rhabdomyolysis and acute kidney injury have been documented for 3-methyl-PCP (Deutsch et al. 2026). Pre-existing renal impairment reduces the capacity to handle myoglobin load from rhabdomyolysis.

pregnancy, breastfeeding

No reproductive or developmental toxicity data exist for 3-Cl-PCP. The high lipophilicity and extensive tissue distribution characteristic of PCP-class compounds (Vd 6.2 L/kg, CNS:serum ratio up to 9:1) predict placental transfer and breast milk accumulation. Contraindicated by precautionary principle.

concurrent MAOI use, MAOI use within washout period

PCP-class compounds inhibit monoamine reuptake (dopamine, norepinephrine, serotonin). Combining this reuptake inhibition with MAOI-induced monoamine accumulation creates risk of serotonin syndrome and hypertensive crisis. No direct evidence exists for 3-Cl-PCP, but the pharmacological mechanism is well-established for the drug class.